Jonathan McNeill, Chief Business Officer at Dyne Therapeutics, Inc. (DYN), sold 198,912 shares at $25.48 ($5.2M) on 2024-03-11, disclosed to the SEC on 2024-03-13.
Scheduled sale ($5.2M) by Chief Business Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $25.46 | 34,663 | $883K | 17.0% |
| 2 | $25.46 | 34,663 | $883K | 17.0% |
| 3 | $26.72 | 54,648 | $1.5M | 28.1% |
| 4 | $26.72 | 54,648 | $1.5M | 28.1% |
| 5 | $27.31 | 689 | $19K | 0.4% |
| 6 | $25.48 | 17,825 |
| $454K |
| 8.7% |
| 7 | $25.71 | 1,776 | $46K | 0.9% |
| Total | $26.16 avg | 198,912 | $5.2M | 100% |
| Filing → |
| DYN | SELL | 2024-08-20 | $122K | — | Filing → |
| DYN | SELL | 2024-06-11 | $114K | — | Filing → |
| DYN | SELL | 2024-05-17 | $143K | — | Filing → |